Trials / Recruiting
RecruitingNCT05830045
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLP2117 | Specified dose on specified days |
Timeline
- Start date
- 2023-05-19
- Primary completion
- 2025-04-30
- Completion
- 2025-12-31
- First posted
- 2023-04-26
- Last updated
- 2024-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05830045. Inclusion in this directory is not an endorsement.